- Home
- PEGA vs VTRS Comparison
PEGA vs VTRS Comparison
Compare PEGA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- VTRS
- Stock Information
- Founded
- PEGA 1983
- VTRS 1961
- Country
- PEGA United States
- VTRS United States
- Employees
- PEGA N/A
- VTRS N/A
- Industry
- PEGA EDP Services
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- PEGA Technology
- VTRS Health Care
- Exchange
- PEGA Nasdaq
- VTRS Nasdaq
- Market Cap
- PEGA 9.4B
- VTRS 11.0B
- IPO Year
- PEGA 1996
- VTRS N/A
- Fundamental
- Price
- PEGA $57.40
- VTRS $8.81
- Analyst Decision
- PEGA Buy
- VTRS Hold
- Analyst Count
- PEGA 14
- VTRS 5
- Target Price
- PEGA $56.04
- VTRS $10.40
- AVG Volume (30 Days)
- PEGA 2.0M
- VTRS 7.5M
- Earning Date
- PEGA 07-22-2025
- VTRS 08-07-2025
- Dividend Yield
- PEGA 0.10%
- VTRS 5.45%
- EPS Growth
- PEGA 61.54
- VTRS N/A
- EPS
- PEGA 1.18
- VTRS N/A
- Revenue
- PEGA $1,676,025,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- PEGA $15.75
- VTRS N/A
- Revenue Next Year
- PEGA $6.23
- VTRS $1.85
- P/E Ratio
- PEGA $48.80
- VTRS N/A
- Revenue Growth
- PEGA 12.47
- VTRS N/A
- 52 Week Low
- PEGA $29.84
- VTRS $6.85
- 52 Week High
- PEGA $60.96
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- PEGA 59.89
- VTRS 42.87
- Support Level
- PEGA $57.08
- VTRS $8.84
- Resistance Level
- PEGA $60.96
- VTRS $9.27
- Average True Range (ATR)
- PEGA 2.16
- VTRS 0.24
- MACD
- PEGA 0.44
- VTRS -0.06
- Stochastic Oscillator
- PEGA 69.28
- VTRS 22.70
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.